Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss ... giant has been racing against rivals such as Eli Lilly to dominate the highly lucrative weight-loss ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Days earlier, Novo Nordisk cut its sales and profit forecast for first time since the launch of Wegovy four years ago.

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Danish drugmaker Novo Nordisk (NVO) is in the red again after announcing CEO Lars Fruergaard Jørgensen is stepping down ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

The boss of the drugs giant Novo Nordisk has been sacked after falling behind in the global race to develop weight-loss ...